Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2000

View Archived Issues

Chiron and Norwegian National Institutes of Public Health formalize meningitis agreement

Pivotal trials of Cangene human growth hormone begin

Genmab completes financing round; company to accelerate human antibody therapeutics development

Millennium submits IND application for ulcerative colitis treatment to FDA

Ibis Therapeutics and Agouron embark on drug discovery collaboration

Gilead begins another multinational phase III trial of once-daily oral anti-HIV drug

MorphoSys licenses HuCAL technology to Eos Biotechnology

New NHLBI study to identify best treatment for mild persistent asthma

Nexell obtains exclusive license to Diaclone antibody portfolio

Serono and PowderJect achieve development milestone

Nastech reports pilot phase I trial results for new formulation of butorphanol

Interneuron licenses rights to PRO-2000

JTT-501 improves insulin resistance and exerts antidiabetic effects with less weight gain

Improvement in insulin sensitivity demonstrated for WAY-123783 in model of severe insulin resistance

Modified CNTF improves glucose tolerance and insulin-dependent signaling in db/db mice

Phase II trial of Genentech's anti-CD18 antibody fails to meet primary objectives

Data from primate and early clinical studies on oral DPP-IV inhibitor presented at ADA meeting

Seretide MDI approved in the U.K. for asthma Rx

Roche seeks approval for Tamiflu pediatric indication

Intermittent neridronate effective in bone disorders and rheumatoid arthritis

Vitamin D3 derivatives synthesized at Teijin, particularly useful for airways diseases

New PDE4/TNF inhibitors with superior physicochemical and pharmacokinetic profile

R.J. Reynolds presents new amine nicotinic acetylcholine receptor agonists

Potent and selective COX-2 inhibitors from Chugai

Immunosuppressive 2-acylquinolines developed by Japanese lab

Neurocrine Biosciences patents new CRF antagonists

LHRH (GnRH) analogue useful for osteoporosis and other bone disorders

Aventis describes production and activity of new antibiotic

Novel Roche compounds for MMP-related diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...